The tumour suppressor role of SETD2 is emerging in several cancer types, including clear cell renal cell carcinoma, breast and lung cancers, acute lymphoblastic leukaemia, high-grade gliomas and gastrointestinal stromal tumours30, 31, 32, 33, 34. Here, SETD2 is linked to clear cell renal carcinoma.